These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 36755495)
21. Plasma Globotriaosylsphingosine Level as a Primary Screening Target for Fabry Disease in Patients With Left Ventricular Hypertrophy. Yamashita S; Saotome M; Satoh H; Kajihara J; Mochizuki Y; Mizuno K; Nobuhara M; Miyajima K; Kumazawa A; Tominaga H; Takase H; Tawarahara K; Wakahara N; Matsunaga M; Wakabayashi Y; Matsumoto Y; Terada H; Sano M; Ohtani H; Urushida T; Hayashi H; Ishii S; Maruyama H; Maekawa Y Circ J; 2019 Aug; 83(9):1901-1907. PubMed ID: 31308318 [TBL] [Abstract][Full Text] [Related]
22. Lysosome-associated protein 1 (LAMP-1) and lysosome-associated protein 2 (LAMP-2) in a larger family carrier of Fabry disease. Pereira EM; do Monte SJ; do Nascimento FF; de Castro JA; Sousa JL; Filho HC; da Silva RN; Labilloy A; Monte Neto JT; da Silva AS Gene; 2014 Feb; 536(1):118-22. PubMed ID: 24334114 [TBL] [Abstract][Full Text] [Related]
24. Systematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease. Deng M; Zhou H; He S; Qiu H; Wang Y; Zhao AY; Mu Y; Li F; Zhao AZ Orphanet J Rare Dis; 2023 Sep; 18(1):275. PubMed ID: 37670350 [TBL] [Abstract][Full Text] [Related]
25. Fabry disease: A fundamental genetic modifier of cardiac function. Tadevosyan A Curr Res Transl Med; 2017; 65(1):10-14. PubMed ID: 28340691 [TBL] [Abstract][Full Text] [Related]
26. Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease. Namdar M; Gebhard C; Studiger R; Shi Y; Mocharla P; Schmied C; Brugada P; Lüscher TF; Camici GG PLoS One; 2012; 7(4):e36373. PubMed ID: 22558451 [TBL] [Abstract][Full Text] [Related]
27. Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation. Chien Y; Chien CS; Chiang HC; Huang WL; Chou SJ; Chang WC; Chang YL; Leu HB; Chen KH; Wang KL; Lai YH; Liu YY; Lu KH; Li HY; Sung YJ; Jong YJ; Chen YJ; Chen CH; Yu WC Oncotarget; 2016 Dec; 7(52):87161-87179. PubMed ID: 27888626 [TBL] [Abstract][Full Text] [Related]
28. Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation. Lavalle L; Thomas AS; Beaton B; Ebrahim H; Reed M; Ramaswami U; Elliott P; Mehta AB; Hughes DA PLoS One; 2018; 13(4):e0193550. PubMed ID: 29621274 [TBL] [Abstract][Full Text] [Related]
29. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients. Rosa Neto NS; Bento JCB; Pereira RMR Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047 [TBL] [Abstract][Full Text] [Related]
31. Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease. Lenders M; Brand E Drugs; 2021 Nov; 81(17):1969-1981. PubMed ID: 34748189 [TBL] [Abstract][Full Text] [Related]
32. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy. Kodama T; Tsukimura T; Kawashima I; Sato A; Sakuraba H; Togawa T Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537 [TBL] [Abstract][Full Text] [Related]
35. Using CRISPR/Cas9-Mediated GLA Gene Knockout as an In Vitro Drug Screening Model for Fabry Disease. Song HY; Chiang HC; Tseng WL; Wu P; Chien CS; Leu HB; Yang YP; Wang ML; Jong YJ; Chen CH; Yu WC; Chiou SH Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27983599 [TBL] [Abstract][Full Text] [Related]
36. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling. Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584 [TBL] [Abstract][Full Text] [Related]
37. Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening. Chen Z; Yin B; Jiao J; Ye T BMC Nephrol; 2024 Feb; 25(1):61. PubMed ID: 38383316 [TBL] [Abstract][Full Text] [Related]
38. Generation of a CRISPR/Cas9-corrected-hiPSC line (DDLABi001-A) from Fabry disease (FD)-derived iPSCs having α-galactosidase (GLA) gene mutation (c.803_806del). Choi JB; Seo D; Do HS; Han YM Stem Cell Res; 2023 Feb; 66():103001. PubMed ID: 36516658 [TBL] [Abstract][Full Text] [Related]
39. Agalsidase-β should be proposed as first line therapy in classic male Fabry patients with undetectable α-galactosidase A activity. Nowak A; Dormond O; Monzambani V; Huynh-Do U; Barbey F Mol Genet Metab; 2022; 137(1-2):173-178. PubMed ID: 36087505 [TBL] [Abstract][Full Text] [Related]
40. Later Onset Fabry Disease, Cardiac Damage Progress in Silence: Experience With a Highly Prevalent Mutation. Hsu TR; Hung SC; Chang FP; Yu WC; Sung SH; Hsu CL; Dzhagalov I; Yang CF; Chu TH; Lee HJ; Lu YH; Chang SK; Liao HC; Lin HY; Liao TC; Lee PC; Li HY; Yang AH; Ho HC; Chiang CC; Lin CY; Desnick RJ; Niu DM J Am Coll Cardiol; 2016 Dec; 68(23):2554-2563. PubMed ID: 27931613 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]